Haleon PLC Sponsored ADR (NYSE:HLN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Haleon PLC Sponsored ADR (NYSE:HLN) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, two have given a buy rating and two have assigned a strong buy rating to the company.

A number of research firms recently commented on HLN. Jefferies Financial Group restated a “buy” rating on shares of Haleon in a research report on Wednesday, September 23rd. Rothschild & Co Redburn cut Haleon from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Wall Street Zen downgraded Haleon from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Research raised shares of Haleon from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research report on Friday, September 25th.

Haleon Trading Up 0.9%

Shares of NYSE HLN opened at $8.79 on Monday. Haleon has a 1-year low of $8.65 and a 1-year high of $11.28. The company has a market cap of $38.68 billion, a PE ratio of 22.55, a P/E/G ratio of 1.97 and a beta of 0.14. The company has a current ratio of 0.69, a quick ratio of 0.52 and a debt-to-equity ratio of 0.38. The company has a 50-day moving average of $9.65 and a two-hundred day moving average of $9.55.

Haleon Cuts Dividend

The business also recently disclosed a dividend, which was paid on Thursday, September 17th. Shareholders of record on Friday, August 14th were paid a dividend of $0.0642 per share. This is a drop from Haleon’s previous dividend of $0.1307. The ex-dividend date was Friday, August 14th. This represents a yield of 132.0%. Haleon’s dividend payout ratio is 30.77%.

Institutional Trading of Haleon

Several large investors have recently modified their holdings of the stock. Western Wealth Management LLC acquired a new stake in shares of Haleon in the 1st quarter valued at approximately $29,000. Annis Gardner Whiting Capital Advisors LLC grew its holdings in shares of Haleon by 402.0% during the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock worth $30,000 after purchasing an additional 2,404 shares during the last quarter. Parkside Financial Bank & Trust increased its stake in shares of Haleon by 20.4% in the second quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company’s stock valued at $58,000 after buying an additional 1,055 shares during the period. Gryphon Financial Partners LLC acquired a new position in Haleon in the 1st quarter valued at approximately $101,000. Finally, NWF Advisory Services Inc. acquired a new position in Haleon in the 1st quarter valued at approximately $102,000. 6.67% of the stock is owned by institutional investors and hedge funds.

About Haleon

Haleon plc (NYSE: HLN) is a global consumer healthcare company headquartered in Weybridge, England. The company develops, manufactures and markets over-the-counter medicines, oral healthcare products, nutritional supplements and other consumer health products sold through pharmacies, retailers and e-commerce channels.

Its portfolio includes well-known brands such as Sensodyne, Polident and parodontax in oral healthcare; Advil, Panadol, Voltaren and Theraflu in pain relief and respiratory care; and Centrum and Emergen-C in vitamins, minerals and supplements.